Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir. The latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus. This is the reason why people living with HIV are unable to stop their antiretroviral treatment.

Clinical Trial Description

This study consists of 2 Parts. Part 1 is a dose escalation phase. This phase is open-label, single dose titration study in adult people living with HIV. There are 3 stages: a screening stage of up to 14 days; on study study treatment stage, where Nivolumab will be administered on Day 7 and a follow-up stage of 126 days (4 months). The maximum total duration on study for each participant enrolled in this phase is 140 days (4.5 months). Part 2 is a double-blind, randomized, placebo controlled clinical trial of a single fixed dose of Nivolumab administered intravenous (IV) infusion compared with placebo in adult people living with HIV. This part of the study will consist of 3 stages: a screening stage of up to 14 days; on study study treatment stage, where Nivolumab/placebo will be administered on Day 0, followed by a follow-up period which includes a 5-week pre-planned analytical treatment interruption (where antiretroviral therapy (ART) is ceased), before the participant re-commences ART. The maximum total duration on study for each participant enrolled in this phase is 200 days (approximately 6.5 months). ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05187429
Study type Interventional
Source University of Melbourne
Contact Barbara Scher
Phone +61 (0)3 8344 0770
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date January 2022
Completion date January 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04585737 - Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF Phase 4
Not yet recruiting NCT03622177 - Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection
Enrolling by invitation NCT05071378 - Leveraging Family-Based Assets for Black MSM In House Ball Communities N/A
Recruiting NCT04568395 - Acute Effects of TCIG vs ECIG in PLWH N/A
Recruiting NCT04887675 - Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI N/A
Not yet recruiting NCT04820933 - Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV Early Phase 1
Completed NCT03584048 - Charlotte Retention in Care Study
Not yet recruiting NCT05187741 - Effect of a Mobile Health Intervention on Treatment Adherence N/A
Recruiting NCT04675255 - Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism N/A
Recruiting NCT05110963 - Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments N/A
Completed NCT03986099 - Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART N/A
Recruiting NCT04971343 - Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
Recruiting NCT04725877 - VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers Phase 1
Recruiting NCT04618198 - Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa Phase 3